Immunotherapy vs Chemotherapy Which Has Fewer Side Effects?

Immunotherapy and chemotherapy produce distinct side effect profiles because they work through entirely different biological mechanisms. Chemotherapy damages all rapidly dividing cells causing bone marrow suppression, hair loss, and gastrointestinal toxicity. Immunotherapy activates the immune system and when that activation overshoots, it causes organ inflammation affecting the lungs, thyroid, liver, and bowel. Which causes fewer side effects depends on the drug, the cancer type, and the patient’s biology.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore, “Patients assume immunotherapy is gentler because it sounds more natural. But immune related colitis, hepatitis, and pneumonitis from checkpoint inhibitors can be severe and life threatening. The side effect profile is different from chemo, not necessarily lighter.”

Chemotherapy targets all rapidly dividing cells. That is what makes it effective against cancer and harmful to healthy tissue at the same time.

• Bone Marrow Suppression:
  Chemo reduces red cells, white cells, and platelets simultaneously. Low white counts raise infection risk and low platelets cause bleeding, both serious enough to delay or dose reduce treatment.
• Hair Loss and Mucositis:
  Hair follicles and gut lining cells divide rapidly and take the same hit as cancer cells. Hair falls out within 2 to 3 weeks of most anthracycline regimens and mouth sores follow gut lining damage throughout the course.
• Nausea and Vomiting:
  Highly emetogenic regimens affect 70% to 80% of patients. Modern antiemetics control it well but don’t eliminate it. Poorly managed nausea leads to malnutrition that compounds every other side effect.
• Long Term Organ Toxicity:
  Cisplatin causes kidney damage and hearing loss. Doxorubicin causes cardiac toxicity at cumulative doses. Oxaliplatin causes peripheral neuropathy that often persists long after treatment ends.

When chemotherapy stops working, Immunotherapy targets cancer through the immune system rather than attacking dividing cells directly.

Immunotherapy doesn’t attack dividing cells. It activates the immune system and that activation sometimes overshoots into healthy tissue.

• Immune Related Colitis:
  Checkpoint inhibitors cause bowel inflammation in 10% to 30% of patients. Severe colitis needs corticosteroids urgently and can be life threatening if missed.
• Endocrine Toxicity:
  Immunotherapy attacks the thyroid, pituitary, and adrenal glands in a proportion of patients. Hypothyroidism occurs in up to 40% on PD1 inhibitors and some effects require lifelong hormone replacement.
• Pneumonitis:
  Immune related lung inflammation occurs in 3% to 5% of patients on checkpoint inhibitors. Breathlessness and dry cough during treatment need immediate CT chest and an immunotherapy hold.
• Patient Selection Matters:
  PDL1 expression, tumour mutational burden, and MSI status predict both who responds best and who carries the highest immune toxicity risk. Right patient selection reduces severe side effects significantly.

Our previous blog on Chemotherapy Resistance is worth a read for understanding how resistance shapes the decision between these two treatment approaches.

Dr. Sandeep Nayak’s team at MACS Clinic selects between immunotherapy and chemotherapy based on molecular profiling, PDL1 expression, and tumour mutational burden. Side effect management protocols for both are built into the treatment plan before the first cycle, not addressed reactively when toxicity appears.

Patient here gets the treatment their tumour’s biology supports, with the full toxicity profile explained before consent. Not the trending option, not the familiar default. Call +91 8035740000 to book your consultation.

Disclaimer: This content is published for educational and informational purposes only.